Trial Profile
Optical Coherence Tomography (OCT) in a Multicenter, Randomized,Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Registrational
- 30 Jan 2013 New trial record